Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 236

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Open access
Feld, Jordan J, Kandel, Christopher, Biondi, Mia J, Kozak, Robert A, Zahoor, Muhammad Atif, Lemieux, Camille, Borgia, Sergio M, Boggild, Andrea K, Powis, Jeff, McCready, Janine, Tan, Darrell H S, Chan, Tiffany, Coburn, Bryan, Kumar, Deepali, Humar, Atul, Chan, Adrienne, O'Neil, Braden, Noureldin, Seham, Booth, Joshua, Hong, Rachel, Smookler, David, Aleyadeh, Wesam, Patel, Anjali, Barber, Bethany, Casey, Julia, Hiebert, Ryan, Mistry, Henna, Choong, Ingrid, Hislop, Colin, Santer, Deanna M, Lorne Tyrrell, D, Glenn, Jeffrey S, Gehring, Adam J, Janssen, Harry L A, Hansen, Bettina E·2021·The Lancet Respiratory Medicine

Abstract

Background To date, only monoclonal antibodies have been shown to be effective for outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate antiviral responses with activity against respiratory pathogens. We aimed to investigate the safety and efficacy of peginterferon lambda in the treatment of outpatients with mild-to-moderate COVID-19. Methods In this double-blind, placebo-controlled trial, outpatients with laboratory-confirmed COVID-19 were randomly assigned to a single subcutaneous injection of peginterferon lambda 180 μg or placebo within 7 days of symptom onset or first positive swab if asymptomatic. Participants were randomly assigned (1:1) using a computer-generated randomisation list created with a randomisation schedule in blocks of four. At the time of administration, study nurses received a sealed opaque envelope with the treatment allocation number. The primary endpoint was the proportion of patients who were negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA on day 7 after the injection, analysed by a χ2 test following an intention-to-treat principle. Prespecified analysis of the primary endpoint, adjusted for baseline viral load, using bivariate logistic regression was done. The trial is now complete. This trial is registered with ClinicalTrials.gov, NCT04354259. Findings Between May 18, and Sept 4, 2020, we recruited 30 patients per group. The decline in SARS-CoV-2 RNA was greater in those treated with peginterferon lambda than placebo from day 3 onwards, with a difference of 2·42 log copies per mL at day 7 (p=0·0041). By day 7, 24 (80%) participants in the peginterferon lambda group had an undetectable viral load, compared with 19 (63%) in the placebo group (p=0·15). After controlling for baseline viral load, patients in the peginterferon lambda group were more likely to have undetectable virus by day 7 than were those in the placebo group (odds ratio [OR] 4·12 [95% CI 1·15–16·73; p=0·029). Of those with baseline viral load above 106 copies per mL, 15 (79%) of 19 patients in the peginterferon lambda group had undetectable virus on day 7, compared with six (38%) of 16 in the placebo group (OR 6·25 [95% CI 1·49–31·06]; p=0·012). Peginterferon lambda was well tolerated, and adverse events were similar between groups with mild and transient aminotransferase, concentration increases more frequently observed in the peginterferon lambda group. Two individuals met the threshold of grade 3 increase, one in each group, and no other grade 3 or 4 laboratory adverse events were reported. Interpretation Peginterferon lambda accelerated viral decline in outpatients with COVID-19, increasing the proportion of patients with viral clearance by day 7, particularly in those with high baseline viral load. Peginterferon lambda has potential to prevent clinical deterioration and shorten duration of viral shedding. Funding The Toronto COVID-19 Action Initiative, University of Toronto, and the Ontario First COVID-19 Rapid Research Fund, Toronto General & Western Hospital Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(20)30566-x

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 236

Metadata

Authors
Feld, J. J., Kandel, C., Biondi, M. J., Kozak, R. A., Zahoor, M. A., Lemieux, C., Borgia, S. M., Boggild, A. K., Powis, J., McCready, J., Tan, D. H. S., Chan, T., Coburn, B., Kumar, D., Humar, A., Chan, A., O'Neil, B., Noureldin, S., Booth, J., Hong, R., Smookler, D., Aleyadeh, W., Patel, A., Barber, B., Casey, J., Hiebert, R., Mistry, H., Choong, I., Hislop, C., Santer, D. M., Lorne Tyrrell, D., Glenn, J. S., Gehring, A. J., Janssen, H. L. A., & Hansen, B. E.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2021-05
Volume
9
Issue
5
Pages
498-510
ISSN
2213-2600 (ISSN-L)
OpenAlex
W3127381644
Cited by
236
References
11
FWCI
15.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. https://app.cochat.ai/papers/10.1016/s2213-2600(20)30566-x
The paper
Feld, J. J., Kandel, C., Biondi, M. J., Kozak, R. A., Zahoor, M. A., Lemieux, C., Borgia, S. M., Boggild, A. K., Powis, J., McCready, J., Tan, D. H. S., Chan, T., Coburn, B., Kumar, D., Humar, A., Chan, A., O'Neil, B., Noureldin, S., Booth, J., . . . Hansen, B. E. (2021). Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(20)30566-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.